diamond rough initi outperform
initi coverag outperform rate
price target continu build pediatr rare diseas player
anticip merger aevi genom medicin gnmx favor view
lymphat malform oppi may see phase
data complement compani intern program ultra-
rare metabol disord oppti potenti approv could
gener valuabl saleabl fda voucher ev suggest
share hold sizabl upsid potenti merger close pipelin progress
transform acquisit diversifi opportun strengthen presenc
ped rare diseas addit interest clinic pipelin aevi deal close
next month also bring season leadership relev develop
commerci experi well larg strateg holder children hospit
philadelphia
may see poc adult-onset still ye ph
antibodi medimmun origin target driver sever auto-inflammatori
diseas signal aosd blockad clinic valid could
set stage single-tri pivot develop believ multipl myeloma
poor prognost marker offer upsid surpris
well lymphat malform effect
use first-gen mtor inhibitor potenti life-threaten condit
often frustrat toxic burden monitor need highly-pot
dual inhibitor oral candid offer much favor
clinic profil success pivot develop could lead nda file
short path-to-prv strategi provid substanti non-dilut fund
candid congenit disord glycosyl drug
indic may begin see approv long-tim use unoptim
nutrit supplement give us develop regulatori comfort prioriti
review voucher issu upon approv would provid ampl sourc
non-dilut capit
could soon monet non-cor asset suit broad patient popul
concurr busi evolut re-posit
nmda receptor antagonist low blood pressur condit abil
safe provid rapid sustain systol bp increas provid key
differenti current option result on-going ph diabet oh
us could catalyz lucr out-licens deal
year price histori cerecor
neurolog pediatr orphan
diseas compani goal
underserv patient popul
analyst certif import disclosur see disclosur
continu build pediatr rare diseas
player anticip merger gnmx favor
view toward clinical-stag pipelin asset adult-
onset still diseas peak us revenu
lymphat malform peak us revenu support
therapeutically-valid mechan action phase
data program may come complement
candid congenit disord glycosyl
peak ww revenu view substanti
de-risk could add valu form
upsid potenti merger close pipelin progress
demonstr proof-of-concept aosd
demonstr proof-of-concept lm
approv achiev singl pivot trial
fda meet outcom develop
initi poc data
initi poc data
initi poc data
seri approv achiev cdg first w/o add
either fail respect develop program
path registr protract
price target base risk-adjust discount cash flow methodolog assum wacc
termin valu beyond due orphan exclus patent expir assign po
achiev peak ww revenu po achiev peak us revenu po
achiev peak us revenu assign po prv valu valu
lack complet plan merger aevi key strateg risk price target assum merger close key downsid
risk clinic develop risk await data proof-of-concept studi well regulatori risk
seri pend upcom fda meet addit risk may aris lower expect market valu prv
within industri financ risk may increas unabl monet either millipr near term
deal materi asset less remun estim
note see stock trade specul appropri risk-toler investor
initi coverag outperform rate price target
continu build pediatr rare diseas player current
merger aevi genom medicin gnmx favor view toward phase
pipelin asset adult-onset still diseas peak us revenu
lymphat malform peak us revenu support
therapeutically-valid mechan action antibodi
treatment potenti rare sever auto-inflammatori disord candid
soon move phase trial adult-onset still diseas aosd peer-
review report posit clinic data anoth antibodi aosd
encourag inhibitor advanc
come month phase trial congenit lymphat malform famili
condit inhibitor sirolimu adopt fraught
liabil meaning limit use believ dual inhibit
bestow favor clinic profil readout program expect
complement candid congenit disord
glycosyl peak ww revenu consist ultrapur oral formul
d-galactos d-mannos l-fucos view
substanti de-risk given long-term use nutrit supplement
approv one could come soon would gener
prioriti review voucher valu could monet form non-
dilut fund cerc ev suggest share hold signific upsid potenti
merger close pipelin progress regist
price target base risk-adjust discount
cash flow methodolog assum wacc termin valu beyond
due orphan exclus patent expir assign po cerc-
achiev peak ww revenu po aevi-
achiev peak us revenu po
achiev peak us revenu assign po prv valu
valu
lack complet plan merger aevi key strateg risk price
target assum merger close key downsid risk clinic develop risk
await data proof-of-concept studi well
regulatori risk seri pend upcom fda meet addit
risk may aris lower expect market valu prv within industri
financ risk may increas unabl monet either
millipr deal materi asset less remun
estim
believ key near-term event includ outcom fda meet
anticip hold goal defin clinic requir
approv seri member treat respect cdg
poc data aosd lm respect
initi data cdg first
begin pivot trial
begin pivot trial
initi poc data
initi poc data
initi poc data
potenti start pivot trial
potenti start pivot trial
potenti fda approv prv
potenti fda approv prv
potenti fda approv prv
potenti fda approv
potenti fda approv prv
inc d-focus biopharmaceut compani base rockvil
md establish leader treatment pediatr orphan diseas
strateg combin asset acquisitions/divestitur last year
compani undergon substanti transform origin focus
neuropsychiatr drug develop current track acquir aevi genom
medicin gnmx next month expect compani soon possess divers portfolio
orphan drug candid variou stage develop also expect
benefit sale multipl prv award upon drug approv next
year could enabl compani self-fund futur oper
expens non-dilut fashion
pivot pediatr healthcar start avadel acquisit
privat fund life scienc vc complet initi
public offer rais fund develop portfolio asset
obtain merck lilli follow clinic setback phase efficaci miss
major depress disord nicotin withdraw late compani
began shift toward pediatr healthcar obtain modest revenu stabl
market product oper small commerci busi
although legaci pipelin asset mostli de-priorit divest recent
work select nmda receptor antagonist support util larg
market current poorly-address condit low blood pressur may offer
particular advantag exist anti-hypotens due mechanist differenti
activ explor monet extern parti
ichorion acquisit provid de-risk ultra-orphan asset entr
septemb expand pediatr strategi acquisit
gain portfolio late-stag drug candid
congenit disord glycosyl cdg class ultra-rar inherit disord
metabol consider paid share stock owe
develop mileston payabl either stock cash cerc discret
candid consist ultrapur oral formul d-galactos d-mannos
l-fucos sugar adopt
treatment paradigm sever cdg serv mitig genet defect
impact physiolog sugar avail dietari supplement none
approv drug product fact drug indic
treatment cdg importantli grant
fda pediatr diseas design elig prioriti review voucher
prv issu upon approv price paid last five
prv transfer sponsor
sinc enrol cdg first intern natur histori
studi cdg patient includ treat sugar supplement
share cumul data fda part anticip meet earli
compani discuss path registr histori lightly-
regul widespread human use substanc absenc approv
therapi cdg set stage approv enabl small pivot studi
short durat place nda submiss time-frame
sale market product portfolio elimin debt provid reduc opex
novemb sold pediatr portfolio aytu bioscienc aytu
plu total valu deal gain cash share aytu
convert prefer stock valu
addit exist royalti oblig coupl variou commerci accrual
would elimin aytu assum debt
assum part avadel acquisit associ commerci infrastructur
sale forc also transfer aytu move estim save
retain profit product millipr cash flow
continu fund oper evalu strateg option millipr
time aytu manag commerci function
aevi acquisit posit pediatr orphan drug innov
expect close quarter
decemb announc intent acquir aevi genom medicin
gnmx gain three clinical-stag candid anti-il-
antibodi develop sever rare auto-inflammatori disord
inhibitor develop congenit lymphat
malform anti-light antibodi current phase
studi pediatric-onset crohn diseas
phase soon enter poc studi
evalu adult-onset still diseas multipl myeloma
studi lymphat malform see readout
late clinically-valid mechan action support
optim posit signal aosd lm could pave way expediti
path registr given unmet need rare disord benefit
myeloma would upsid surpris could trigger partner interest sizabl
ahead readout see initi data less
favor toward program prospect mainli due struggl encount
histor drug develop campaign target despit attract given
role immun system homeostasi denot wildcard potenti program
deal pay stock also issu conting valu right
cvr paid upon enrol first patient phase studi
relat within two year merger paid
upon fda approv either within five year cvr may paid
either cash stock cerc discret
merger prospectu avail gnmx sharehold vote schedul
held expect vote talli favor deal close shortli
mechan current near-term capit
estim current cash howev compani sever
mean could bring near-term capit altern equiti capit
millipr would expect millipr franchis could sold
repres annual cash flow gener believ
current discuss potenti buyer asset
armistic backstop connect plan merger holder armistic
enter backstop agreement may request armistic buy
share less gross proce receiv sale
equiti equity-link secur sale certain asset believ
millipr sell price armistic equal close price date
notic submit armistic agreement expir march
aytu equiti prefer stock aytu held convert common
time saleabl follow aytu sharehold approv vote
special aytu sharehold meet set januari sharehold approv
receiv share convertible/transfer start earli may follow six-
model assum rais armistic
agreement sale aytu hold conserv assum
millipr sold sale aytu equiti occur
lock-up period end
adult-onset still diseas disord lack
adult-onset still diseas aosd inflammatori disord first describ
cardin symptom highli frequent often daili twice-daili fever joint
pain intermitt rash patient experi addit symptom includ
gener skelet muscl pain sore throat spleen lymph node
case liver enlarg sharp chest pain due inflamm outer
line lung and/or heart may occur infrequ seriou potenti fatal
complic macrophag activ syndrom uncontrol activ
prolifer lymphocyt macrophag result multipl organ
diagnosi aosd made clinic ground laboratori abnorm includ
high erythrocyt sediment rate esr elev c-reactiv protein crp
marker system inflamm leukocytosi neutrophilia
thrombocytosi elev liver enzym elev ferritin anemia also observ
caus multifactori diseas unknown uncertain whether
origin way among patient genet element infecti trigger
suggest import proof infecti caus
evid support role genet factor mix henc aosd
consid diagnosi exclus mean condit infect
malign rule prior make diagnosi diagnost
test aosd
exhibit pathogen mechan aosd
propos pathogen includ numer virus well bacteria yersinia
enterocolitica mycoplasma pneumonia regard genet factor human
leukocyt antigen associ aosd
french studi find yet confirm famili case
cours aosd typic take one three formsmonophas intermitt
monophas pattern diseas last week month complet resolv
within less year case system featur fever rash inflamm
outer line heart lung spleen liver enlarg predomin
group
patient intermitt pattern one diseas flare without
articular symptom experi complet remiss episod last
week one two year although subsequ flare unpredict
tend shorter less sever initi episod
chronic pattern patient persist activ diseas articular
per literatur report one-third patient fall three diseas pattern
although uncommon either monophas intermitt varieti evolv
chronic articular type
aosd adult system juvenil idiopath arthriti
aosd member group auto-inflammatori disord character excess
innat immun respons share mani similar system juvenil idiopath
arthriti sjia primari distinct diagnosi patient age
year aosd/sjia much rarer juvenil idiopath arthriti jia
diseas primarili limit joint estim us preval jia
us sjia account case jia
aosd poorli current option
broadli treatment goal aosd control physic sign symptom
inflamm fever rash morn stiff joint pain swell
secondarili control laboratori indic inflamm esr crp elev
prevent end organ damag includ joint injuri major organ
complic minim risk advers effect therapi includ long-
term effect glucocorticoid
random trial compar therapeut option uncommon disord lack
direct evid treatment efficaci deriv princip observ studi
clinic experi treatment choic larg empir increas use il-
inhibitor earli therapi support use inhibitor first-lin therapi
sever aosd princip base upon evid support use agent
children sjia
aosd patient treat amgn kineret recombin human receptor
antagonist system articular manifest improv patient
glucocorticoid-spar effect signific reduct number patient
methotrex sulfasalazin leflunomid hydroxychloroquin gold salt observ
lli actemra shown significantli reduc articular system
manifest acute-phas marker prednison dosag patient aosd
although nvss ilari canakinumab antagonist dose monthli indic
treatment aosd patient respond inadequ previou therapi
nsaid system corticosteroid result control clinic studi
current avail placebo-control phase ist termin due enrol
challeng caus ilariss avail market drug
sever diseas guid initi choic therapi subsequ treatment decis
base upon patient respons
mild diseas nsaid naproxen ibuprofen typic use up-front alon
effect patient glucocorticoid prednison disease-
modifi anti-rheumat drug dmard tnf inhibitor recommend next
use outset advanc diseas
methotrex ra-lik regimen recommend glucocorticoid
patient minim system symptom present predominantli arthriti
glucocorticoid effect prevent progress joint damag patient
articular involv undesir long-term side effect tnf inhibitor
 jnj remicad recommend patient achiev control diseas
rash fever symptom system inflamm yet without
signific clinic joint involv sign eros joint diseas amgn kineret
inhibitor prefer actemra tnf inhibitor altern
respond kineret ilari may use respond kineret
toler daili inject schedul
altern refractori typic therapi includ regn arcalyst
fusion protein approv cap hereditari auto-inflammatori disord rhhbi
rituxan ivig cyclosporin
put target aosd
evid suggest play major role aosd pathogenesi member
famili pro-inflammatori cytokin produc macrophag osteoblast
induc sever inflammatori reaction stimul product releas
interferon-gamma ifn immun cell aosd shown circul
level correl clinic biolog marker diseas activ exemplifi
recent studi found serum level elev normal
sjia aosd patient exhibit
exhibit level elev aosd associ diseas sever
biolog activ tightli control bind protein
natur occur inhibitor bind interleukin high affin use
conduct open-label two-arm phase clinic studi aosd enrol
site switzerland germani franc investig therapeut potenti
block activ treatment aosd tadekinig alfa given sc inject
week either per dose
studi popul heterogen respect diseas present
use glucocorticoid half receiv csdmard one-third
receiv biolog dmard appear difficult-to-treat sampl elig requir
activ aosd defin yamaguchi criteria exhibit plu either fever crp
despit treatment prednison and/or csdmard
exhibit yamaguchi criteria aosd
temperatur week
exclud infect malign rheumat diseas
adult still consid five incl two major criteria met
receiv drug achiev earli three week predict respons
criteria up-titr anoth week earli respond dose
increas group group occur
two patient allow physician discret
studi blockad led respons patient respons pre-
defin either three week normal bodi temperatur either least
decreas baselin crp level normal crp valu mg/l
week improv swollen joint count sjc tender joint count
tjc baselin valu accord assess
decreas crp level compar baselin valu reduct normal level
normal ferritin notabl four patient undetect free level
exhibit tadekinig alfa efficaci aosd
respond week fever
respond week
improv skin rash observ time exhibit skin rash
baselin six patient week reduct also median
prednison dosag decreas baselin week
commonli report advers event aggreg tadekinig alfa experi
ra psoriasi inject site reaction mild case apart
isr safeti signal appar
phase data publish case report two trial subject
continu tadekinig alfa extend period time one year two year
respect maintain treatment respons throughout time drug
abl meaning taper prednison dosag
ab appear pursu phase develop tadekinig alfa two
syndrom xiap defici compani appear take drug
forward aosd reason decis may includ lack respons certain
patient possibl due inadequ abil reduc level short
level inject site reaction
exhibit skin rash tadekinig alfa
phase antibodi develop aosd
high affin kd pm fulli human neutral monoclon antibodi
potent durabl inhibit interleukin human gener
medimmun azn initi investig copd
manag although develop termin earli follow lack
clinic efficaci set phase singl ascend dose trial
mg iv demonstr potent dose-depend suppress well
clean safeti profil drug-rel sae phase
note observ advers effect level noael observ
monkey tox studi comprehens pre-clin packag facilit rapid
project sale potenti aosd
mani rare disord public avail aosd rate deriv
narrow region studi exampl one retrospect studi base western
franc estim annual incid aosd incid
system juvenil idiopath arthriti sjia aosd believ adult
form estim children year aevi recent
commiss market research ascertain preval aosd major
pharmaceut market exhibit per research aosd patient may
character sever chronic
exhibit preval aosd
model assum us patient current activ treat
sever chronic aosd peak use impli peak
annual sale opportun owe low double-digit royalti net sale
azn estim
also look multipl myeloma
blockad may also hold potenti treatment approach multipl myeloma
support evid indic entiti may independ determin
poor surviv reduc level prolong surviv rodent model shown
japanes group among multipl myeloma patient low
median significantli longer overal surviv mo vs mo
patient high median notabl appear
associ bone marrow level classic risk factor
motiv concept also evalu ascertain potenti clinic
activ myeloma set model includ revenu
exhibit independ determin poor surviv myeloma
readout aosd myeloma earli
expect enter one poc studi aosd myeloma
expect provid data late acr criteria use
assess aosd
cerc/gnmx access unformul bulk materi held frozen storag
medimmun quantiti suffici support clinic studi well
phase non-clin six-month chronic tox studi conduct
base result determin forward strategi asset
aosd result support go-decis acceler approv indic could
enabl singl pivot trial pend success indic nda
submiss could submit
would expect data support myeloma viabl indic develop
drive signific partnership interest establish compani oncolog
lymphat malform famili potenti life-threaten
lymphat malform non-malign mass consist fluid-fil channel
space thought result abnorm develop lymphat system
system consist network vessel transport lymph thin wateri
fluid tissu organ bloodstream help protect bodi
infect diseas lymphat vessel drain lymph node filter virus
bacteria gener cell immun system retain antibodi
lymphat malform impact health typic compress obstruct nearbi
structur henc specif symptom sever vari base upon size
massiv specif locat usual enlarg slowli tandem overal bodili
growth patient age certain event puberti infect trauma
bleed lymphat malform caus grow rapidli occasion
lymphat malform caus swell local area may disfigur
especi occur area face extrem impair function
depend upon extent mass imping upon particular structur organ
exampl neck pressur trachea caus difficulti breath
pelvi caus urinari obstruct
addit complic lm frequent aris infect due
low number lymphocyt area inflamm well hemorrhag
nearbi blood vessel infect caus overli skin develop cellul becom
red hot tender due bacteri infect recurr caus disfigur
bleed lymphat malform caus rapid pain harden swell
rate morbid mortal vari among variou lm type tend high
exampl mortal rate gorham stout diseas gsd
median overal surviv kaposiform lymphangiomatosi year
respect
estim publish inform aggreg us preval
four common lm form gla gsd cca per
mutat along mtor pathway common driver lymphat malform
biolog basi lymphat malform remain unknown activ
mutat along pathway identifi caus
larg portion mutat tend occur somat non-inherit fashion
mammalian target rapamycin mtor serine/threonine-specif protein kinas
form core compon two protein complex
togeth regul cell growth metabol prolifer surviv kinas
shown govern normal vascular growth develop enhanc mtor
signal increas express vascular endotheli growth factor vegf
mtor well-establish target cancer therapi alloster inhibitor mtor
approv sever solid malign exhibit
overactiv mtor pathway vascular abnorm provid molecular
rational mtor inhibit sirolimu demonstr clinic util lymphat
malform exampl open-label phase trial enrol patient
varieti complic lm type control previou medic sclerotherapi
and/or surgeri sirolimu given oral cours day fifty-seven
patient evalu efficaci end cours six evalu
end cours result shown exhibit
exhibit result studi sirolimu lymphat malform
observ efficaci provid support treatment strategi advers event
burdensom notwithstand essenti treatment option avail
impact upon diseas process sirolimu use off-label treatment
patient lymphat malform complianc reportedli low due
safeti toler includ high rate stomat also due burden
frequent monitor requir sirolimuss label featur black box warn
immunosuppress malign develop
next-gen mtor inhibitor develop
unlik sirolimu avail mtor inhibitor target
potent inhibit signal complex potenti
allow complet truncat aberr signal pathway follow
potenti improv safeti efficaci mtor inhibit
lm
rapidli absorb tmax within exhibit estim termin half-lif
system exposur dose-proport comprehens pre-clin toxicolog
packag complet compound evalu
dose-escal phase trial patient advanc solid cancer complet
astellas/osi studi dose-escal three schedul three
consecut days/week daili dose-limit toxicitt daili
develop oncolog astella discontinu upon determin
target efficaci dose evid support cerc view
lymphat malform adequ treat dose significantli
seek initi phase proof-of-concept studi lm patient
believ approv could secur timelin remain
project sale potenti
estim total address market lm lm
patient model reach peak penetr
fraction impli peak annual sale opportun owe mid-single-
digit tier royalti net sale astellas/osi estim
congenit disord glycosyl
congenit disord glycosyl cdg famili diseas
underli biochem defect lie within process newly-synthes
protein lipid modifi sugar tree glycan glycosyl highli
regul play critic role determin protein structur function stabil
henc import integr half protein human bodi
glycosyl occur sequenti coordin action seri
enzym within endoplasm reticulum golgi complex organel lie
downstream rough endoplasm reticulum er protein translat
ribosom major protein synthes rer undergo glycosyl
shown exhibit glycan carbohydr consist sever sugar unit
may attach protein either nitrogen oxygen atom certain amino
acid residu side chain n- o-glycosyl respect defect occur either
process cdg may also stem glycolipid glycosylphosphoinositol
anchor synthesi defect well abnorm multipl glycosyl
nucleotide-sugar transport o-mannosyl among other among cdg report
date protein n-glycosyl abundantli impair cerc lead indic
mpi character defect n-glycosyl
approxim gene believ encod protein enzym
transport involv variou glycosyl step defici absenc
one profound effect health develop often detect
infanc given cdg typic caus mutat specif gene cdg
inherit autosom recess condit abnorm gene
trait inherit parent cdg exhibit autosom recess
inherit pattern howev small number cdg cdg-i
cdg-iim inherit x-link
due essenti role play glycosyl protein across divers physiolog
function cdg typic present multi-system abnorm within
first year life clinic phenotyp rang mild sever
common sign development delay failur thrive hypotonia neurolog
abnorm hepatopathi coagulopathi affect individu may also present
eye skin cardiac diseas well facial dysmorph neurolog chang
cognit delay seen major affect individu given broad clinic
genet etiolog cdg clinic diagnosi reli high index suspicion multi-
system diseas although rate diagnos rise
cdg type describ sinc first report dr jaak jaeken
univers leuven colleagu ultra-rar disord
fewer known patient nearli lack approv adequ therapeut
option time preval individu congenit disord
glycosyl combin preval unknown due rariti howev
preval estim cdg-ia
screen diagnost resourc increasingli access
serum carbohydr defici transferrin cdt analysi also known isoelectr
focus first-lin screen test patient suspect cdg limit
detect n-glycosyl defect sialic acid defici abnorm result
follow cdg panel/whole-exom we /whole genom wg sequenc well
dolichol-link glycan analysi identifi involv gene earli diagnosi
import cdg treatabl
substrat replac therapi cdg
cur option current avail cdg howev
recogn take daili oral dose sugar substrat
defect enzym certain cdg provid meaning clinic benefit scienc
behind incomplet understood may involv circumv disrupt
glycosyl recruit complementari mechan upregul
exhibit therapeut mechan substrat supplement cdg
efficaci certain sugar togeth safeti toler led sever
becom standard care exampl d-galactos use d-
mannos use mpi l-fucos use exhibit formal
clinic trial run clinic pre-clin observ report
peer-review literatur inform dose guidelin evolv use experi
guid blood biomark test glycosyl level circul
transferrin dose level gener correl weight nearli case
dietari carbohydr enrich littl impact bodi weight
exhibit select cdg treatment
enzymat convers
phosphat
enzymat interconvers
phosphat
enteropathi rescu
transmembran transport gdp-fucos
restor e- p-selectin ligand
none sugar approv pharmaceut indic
regulatori perspect nutrit supplement patient abl
obtain would distinct advantag regul
prescript drug includ standard reliabl sourc product
current obtain variou bulk supplier assur avail
high puriti lot-to-lot consist current form ultrapur consist
uneven elig reimburs supplement reimburs
avail data support dose standard dose current done ad hoc
basi furthermor patient abil receiv treatment rare disord
indic drug typic lead increas diagnos seen prior
orphan drug introduct stand reason avail approv therapi
cdg would effect bring patient system diagnost workup
potenti treatment kol spoken agre
substrat replac subject prescript drug regulatori requir would
engend meaning improv cdg therapeut condit qualiti
life patient famili
global cdg patient registri establish
collabor patient advocaci organ cdg medic genet
compani establish first global cdg registri known
cdg connect invita cdg panel analyz gene associ
disord cover mpi
test use diagnosi patient cdg suspect due clinic
symptom biochem find abnorm transferrin isoelectr focus
patient defect either type type ii n-link glycosyl abnorm
pattern transferrin isoelectr focus
conduct cdg first retrospect trial peopl cdg purpos
cdg first learn natur cours cdg diseas also
understand effect dietari supplement sugar health trial conduct
cdg center sever countri first patient enrol juli
enrolle like steadi regimen substrat replac mean
nutrit supplement trial also open patient
period assess routin practic
upcom fda meet defin path registr
plan meet fda discuss remain requir
secur approv data cdg first share
agenc expect one singl arm open label pivot trial candid
suffici registr primari endpoint consist blood-
plan refer inform sever third-parti sourc literatur
articl toxicolog data licens support eventu nda
seek approv pathway
grant fda ema orphan drug
design provid market exclus seven ten year respect
elig acceler approv plan request fda breakthrough
therapi design pend data cdg first evid clinic benefit
current expect submit nda
due rariti cdg cerc pivot trial indic would exceedingli
small patient exampl increas comfort cerc regulatori
strategi tini pivot trial biomark endpoint complement prior
patient report wellstat xuriden fda approv septemb
treatment hereditari orot aciduria hoa genet disord caus mutat
reduc activ uridin monophosph synthas ump xuriden
pyrimidin analog serv replac uridin hoa patient synthes
adequ amount back-up orot acid convert
ump lead grievou illnessanemia development retard accord
fda known case hoa prior xuriden product approv
fda approv xuriden base evid singl arm clinic trial four
patient hoa patient receiv drug daili six week benefit
measur look stabil blood cell count patient continu receiv
xuriden least nine month dosag daili six-
week six-month assess xuriden treatment result stabil
hematolog paramet four trial patient advers reaction report
xuriden approv also base evid medic literatur
describ patient hoa treat activ ingredi xuriden
sale potenti cerc cdg franchis
report all-inclus incid cdg rang
mpi togeth account cdg case accord scientif
accord mpi consist patient ww
compani assign sale opportun
exhibit cdg address market commerci opportun per est
model project ww aggreg sale
achiev seventh last year us orphan exclus period
note anoth three year eu orphan protect
current regul sponsor receiv fda approv drug biolog
receiv pediatr diseas design rpdd issu prioriti
review voucher prv redeem sponsor anoth compani
limit transfer receiv prioriti review approv decis
render six month vs ten month standard review subsequ market
applic differ product voucher expir
compani may hold voucher eventu benefit pipelin
asset smaller less-establish compani might elect sell voucher exchang
non-dilut capit need fund oper busi develop buyer
typic fully-integr cash flow-gener biotech/pharma compani
valu earlier launch and/or longer market exclus upcom large-market
product could substanti
shown exhibit steadi market prioriti review
voucher price high paid
recent transact rang
exhibit prv issu sold sinc program incept
data includ type prioriti review voucher http //priorityreviewvouch org ce
prioriti review voucher program neglect diseas sunset
program rare pediatr diseas current set expir octob although
drug design rare pediatr treatment still receiv voucher drug
approv octob program elig renew howev congress
renew program sever time alreadi
cerc three advanc substrat replac therapi
receiv design mean prv issu upon approv
candid indic would sell cash would
use off-set oper expens
larg market potenti long-dat ip non-cor asset could drive
oral potent nmda receptor antagonist specif
subunit nmol/l dose-proport pharmacokinet rapid onset
action tmax suitabl once-daili dose origin
innov merck
follow termin develop major depress disord due lack efficaci
observ robust blood pressur effect motiv evalu
potenti address condit associ hypotens posit effect blood
pressur entir surpris blood pressur increas seen
nmda antagonist
recent conduct placebo-control singl escal dose studi patient
parkinson diseas associ neurogen orthostat hypotens noh
common troublesom co-morbid impair vasoconstrict result inadequ
norepinephrin releas sympathet vasomotor neuron fourteen patient
random receiv singl escal dose placebo four
studi visit patient receiv placebo least one visit patient return
fifth studi visit random receiv either
placebo visit patient complet orthostat stand test ost pre-
dose hour post-dos
exhibit improv blood pressur upon stand consist predict pk across dose studi
result exhibit demonstr rise sbp upon stand earli one hour
post dose continu across six-hour studi period highest dose
rapid clinic meaning sbp sustain increas achiev
baselin placebo maximum improv strong
dose-rel consist plasma concentr across dose test
seriou advers event dose consid safe well toler
may offer advantag current option orthostat hypotens
earli sustain treatment effect seen appear differenti
candid product indic noh lundbeck northera well
northera droxidopa fda-approv product noh pro-drug
norepinephrin northera work via adrenerg pathway specif indic
symptomat treatment adult noh caus primari autonom failur well
dopamin -hydroxylas defici non-diabet autonom neuropathi start
tid titrat tid max dose tid
addit contain black box warn supin hypertens high blood pressur
lie northera label state effect beyond two week
establish report least one-third patient inadequ
respond drug despit drawback northera gener us
midodrin fda approv symptomat oh pro-drug metabol
adrenerg agonist receiv off-label use noh addit use non-
neurogen form sever contraind includ acut kidney diseas
like northera increas risk high blood pressur lie
box warn toler issu includ paresthesia dysuria pruriti chill
accord symphoni wac sale
current evalu diabet orthostat hypotens
orthostat hypotens common clinic manifest diabet neuropathi
began enrol clinic poc studi diabet oh octob
ascertain effect blood pressur popul random double-blind
placebo-control crossov studi conduct two in-clin visit
visit patient receiv either singl dose placebo undergo seri
orthostat test period plasma glucos also follow expect
see top line data
observ rais blood glucos diabet believ could offer
attract potenti diabet oh result would also support intra-dialyt
oh idh phenomenon patient chronic kidney diseas ckd experi
hypotens episod hemodialysi session patient popul
intra-dialyt hypotens attract potenti opportun
idh believ occur dialysi session incid like
continu increas grow number elderli patient develop ckd
number diabet patient ckd progress increas much room
improv manag idh midodrin primarili use
contraind problemat given common co-morbid ckd patient
henc partner possibl may lie endocrinology-focus pharma compani
either two domin dialysi provid freseniu
exhibit posit serv sever larg poorly-address popul hypotens risk
patent protect
although year remain origin composition-of-matt patent
expect recent polymorph patent issu februari jointli assign
merck extend protect late
compani report oppenheim co inc estim
except per share data fy revenu forc y/i growth in-process intang fair valu conting oper oper marginchang fair valu warrant liabil unit purchas option incom expens incom expens sale net incom attribut average dil share y/i outperform
compani report oppenheim co inc
mm except per share data fy current properti equip intang asset restrict cash net current total liabil sharehold equitytot current long term debt net current conting consider net current defer tax liabil licens long-term total common prefer addit paid-in conting issuabl retain earn accumul total stockhold total liabil stockhold cerecor
exhibit cerc manag forma gnmx acquisit
michael cola current ceo aevi genom medicin becom ceo
follow gnmx acquisit join aevi presid ceo
septemb prior join aevi mr cola serv presid specialti
pharmaceut shire plc global specialti pharmaceut compani
april join shire evp global therapeut busi unit
portfolio manag prior join shire inc
growth capit provid life scienc technolog compani serv
presid life scienc group safeguard mr cola serv chairman
ceo clarient inc cancer diagnost compani subsequ acquir ge
healthcar chairman laureat pharma inc full-servic contract
manufactur organ serv research-bas biolog compani prior
mr cola held senior posit product develop
commerci astramerck top us pharmaceut compani
astrazeneca global biopharmaceut compani mr cola receiv biolog
physic ursinu colleg biomed scienc drexel
univers serv board director inc
therapeut current serv chairman board governor boy
girl club philadelphia mr cola also serv life scienc pennsylvania board
formerli name pennsylvania
mr miller bring year experi wealth financi knowledg
senior execut extens hands-on experi manag financi oper
support enterpris growth across health scienc bio-tech pharmaceut
sector previou role sucampo pharmaceut respons build
financ organ effect support compani rapid growth
ultim result merger earli prior sucampo
serv variou progress financ manag role eppendorf
kpmg llp mr miller strength includ lead build compani financ
infrastructur creat scalabl world-class organ make excel fit
strateg imper growth innov new mr miller hold
 degre account villanova univers certifi public account
garri neil current cso aevi genom medicin becom
follow gnmx acquisit prior join aevi septemb dr neil held
number senior posit pharmaceut industri academia ventur capit
includ corpor vice-president scienc technolog johnson johnson group
presid johnson johnson pharmaceut research develop vice-president
merck kgaa/emd vice-president clinic research astra zeneca astra
merck leadership number import new medicin treatment
cancer anemia infect central nervou system psychiatr disord pain
genitourinari gastrointestin diseas gain initi expand approv dr neil
hold univers saskatchewan univers
saskatchewan colleg medicin complet postdoctor clinic train intern
medicin gastroenterolog univers toronto dr neil also complet
postdoctor research fellowship research institut scripp clinic
found chairman pharmaceut industri consortium transceler
biopharmaceut inc remain board also serv board
reagan udal foundat past member board
foundat nation institut fnih scienc manag
review board nih past chairman pharmaceut research
manufactur associ phrma scienc regulatori execut committe
phrma foundat board
dr calia bring year biopharmaceut experi clinic develop
across drug devic sector healthcar strength includ pre-clin
clinic develop global regulatori submiss dr calia extens
experi neurolog well rare diseas strong track record
compound develop pipelin progress well build research
develop organ previou experi includ serv vice presid
global product develop sucampo held varieti research
develop posit clinic non-clin role expand leadership
shire hgt genzym dr calia strong background early-stag asset
develop well clinic trial experi add clinic
organ compani enter phase trial two neurolog asset dr
calia obtain ph bio-organ chemistri tuft univers
biolog suffolk univers
mr harrel great breadth biopharmaceut industri experi sinc may
owner princip nsci group inc privately-held medic
commun educ compani focus new busi
develop brand strategi mr harrel vice presid gener manag
specialti pharmaceut covidien run commerci oper group
area pain manag late
vice presid market medimmun inc respons global pediatr
infecti diseas franchis februari mr harrel held variou
commerci posit centocor inc increas level respons
manag focus market immunotherapi cardiovascular product
began career field sale hospit sale rhone-poulenc rorer
career help commerci market three blockbust brand
hold degre busi administr doubl major market
econom stamford univers
stock price compani mention report
